Glycolysis Metabolites and Risk of Atrial Fibrillation and Heart Failure in the PREDIMED Trial
Por:
Becerra-Tomas, N, Ruiz-Canela, M, Hernandez-Alonso, P, Bullo, M, Li, J, Guasch-Ferre, M, Toledo, E, Clish, C, Estruch, R, Ros, E, Fito, M, Lee, C, Pierce, K, Aros, F, Serra-Majem, L, Liang, L, Razquin, C, Gomez-Gracia, E, Martinez-Gonzalez, M, Hu, F, Corella, D and Salas-Salvado, J
Publicada:
1 may 2021
Resumen:
The increased prevalence of atrial fibrillation (AF) and heart failure (HF) highlights the need to better understand the mechanisms underlying these cardiovascular diseases (CVDs). In the present study, we aimed to evaluate the association between glycolysis-related metabolites and the risk of AF and HF in a Mediterranean population at high risk of CVD. We used two case-control studies nested within the PREDIMED trial. A total of 512 incident AF cases matched to 734 controls, and 334 incident HF cases matched to 508 controls, were included. Plasma metabolites were quantified by using hydrophilic interaction liquid chromatography coupled with high-resolution negative ion mode MS detection. Conditional logistic regression analyses were performed. The results showed no association between baseline plasma glycolysis intermediates and other related metabolites with AF. Only phosphoglycerate was associated with a higher risk of HF (OR (for 1 SD increase): 1.28; 95% CI: 1.06, 1.53). The present findings do not support a role of the glycolysis pathway in the pathogenesis of AF. However, the increased risk of HF associated with phosphoglycerate requires further studies.
Filiaciones:
Becerra-Tomas, N:
Univ Valencia, Dept Prevent Med, Valencia 46010, Spain
Univ Rovira & Virgili, Dept Biochem & Biotechnol, Human Nutr Unit, Reus 43201, Spain
Inst Invest Sanitaria Pere Virgili IISPV, Reus 43204, Spain
Inst Hlth Carlos III ISCIII, Consorcio Ctr Invest Biomed Red, MP CIBEROBN, Madrid 28029, Spain
Ruiz-Canela, M:
Inst Hlth Carlos III ISCIII, Consorcio Ctr Invest Biomed Red, MP CIBEROBN, Madrid 28029, Spain
Univ Navarra, Dept Prevent Med & Publ Hlth, Pamplona 31008, Spain
Navarra Inst Hlth Res, IdiSNA, Pamplona 31008, Spain
Hernandez-Alonso, P:
Univ Rovira & Virgili, Dept Biochem & Biotechnol, Human Nutr Unit, Reus 43201, Spain
Inst Invest Sanitaria Pere Virgili IISPV, Reus 43204, Spain
Inst Hlth Carlos III ISCIII, Consorcio Ctr Invest Biomed Red, MP CIBEROBN, Madrid 28029, Spain
Univ Malaga IBIMA, Virgen Victoria Univ Hosp, Dept Endocrinol & Nutr, Malaga 29010, Spain
Bullo, M:
Inst Invest Sanitaria Pere Virgili IISPV, Reus 43204, Spain
Inst Hlth Carlos III ISCIII, Consorcio Ctr Invest Biomed Red, MP CIBEROBN, Madrid 28029, Spain
Univ Rovira & Virgili URV, Dept Biochem & Biotechnol, Fac Med & Hlth Sci, Reus 43201, Spain
Li, J:
Harvard TH Chan Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA
Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA
Guasch-Ferre, M:
Harvard TH Chan Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA
Brigham & Womens Hosp, Dept Med, Channing Div Network Med, 75 Francis St, Boston, MA 02115 USA
Harvard Med Sch, Boston, MA 02115 USA
Toledo, E:
Inst Hlth Carlos III ISCIII, Consorcio Ctr Invest Biomed Red, MP CIBEROBN, Madrid 28029, Spain
Univ Navarra, Dept Prevent Med & Publ Hlth, Pamplona 31008, Spain
Navarra Inst Hlth Res, IdiSNA, Pamplona 31008, Spain
Clish, C:
Broad Inst Harvard & MIT, Boston, MA 02142 USA
Estruch, R:
Inst Hlth Carlos III ISCIII, Consorcio Ctr Invest Biomed Red, MP CIBEROBN, Madrid 28029, Spain
Univ Barcelona, Inst Invest Biomed August Pi Sunyer IDIBAPS, Hosp Clin, Dept Internal Med, Barcelona 08036, Spain
Ros, E:
Inst Hlth Carlos III ISCIII, Consorcio Ctr Invest Biomed Red, MP CIBEROBN, Madrid 28029, Spain
Univ Barcelona, Hosp Clin, Dept Endocrinol & Nutr, Lipid Clin, Barcelona 08036, Spain
Fito, M:
Inst Hlth Carlos III ISCIII, Consorcio Ctr Invest Biomed Red, MP CIBEROBN, Madrid 28029, Spain
Inst Recerca Hosp del Mar, Cardiovasc & Nutr Res Grp, Barcelona 08036, Spain
Lee, C:
Harvard TH Chan Sch Publ Hlth, Dept Mol Metab, Boston, MA 02132 USA
Pierce, K:
Broad Inst Harvard & MIT, Boston, MA 02142 USA
Aros, F:
Inst Hlth Carlos III ISCIII, Consorcio Ctr Invest Biomed Red, MP CIBEROBN, Madrid 28029, Spain
Univ Hosp Alava, Dept Cardiol, Vitoria 01009, Spain
Serra-Majem, L:
Inst Hlth Carlos III ISCIII, Consorcio Ctr Invest Biomed Red, MP CIBEROBN, Madrid 28029, Spain
Univ Las Palmas Gran Canaria, Res Inst Biomed & Hlth Sci IUIBS, Las Palmas Gran Canaria 35001, Spain
Complejo Hosp Univ Insular Materno Infantil CHUIM, Canary Hlth Serv, Serv Prevent Med, Las Palmas Gran Canaria 35001, Spain
Liang, L:
Harvard TH Chan Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA
Razquin, C:
Inst Hlth Carlos III ISCIII, Consorcio Ctr Invest Biomed Red, MP CIBEROBN, Madrid 28029, Spain
Univ Navarra, Dept Prevent Med & Publ Hlth, Pamplona 31008, Spain
Navarra Inst Hlth Res, IdiSNA, Pamplona 31008, Spain
Gomez-Gracia, E:
Univ Malaga, Sch Med, Dept Prevent Med & Publ Hlth, Malaga 29010, Spain
Martinez-Gonzalez, M:
Inst Hlth Carlos III ISCIII, Consorcio Ctr Invest Biomed Red, MP CIBEROBN, Madrid 28029, Spain
Univ Navarra, Dept Prevent Med & Publ Hlth, Pamplona 31008, Spain
Navarra Inst Hlth Res, IdiSNA, Pamplona 31008, Spain
Harvard TH Chan Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA
Hu, F:
Harvard TH Chan Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA
Brigham & Womens Hosp, Dept Med, Channing Div Network Med, 75 Francis St, Boston, MA 02115 USA
Harvard Med Sch, Boston, MA 02115 USA
:
Univ Valencia, Dept Prevent Med, Valencia 46010, Spain
Inst Hlth Carlos III ISCIII, Consorcio Ctr Invest Biomed Red, MP CIBEROBN, Madrid 28029, Spain
Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA
Salas-Salvado, J:
Univ Rovira & Virgili, Dept Biochem & Biotechnol, Human Nutr Unit, Reus 43201, Spain
Inst Invest Sanitaria Pere Virgili IISPV, Reus 43204, Spain
Inst Hlth Carlos III ISCIII, Consorcio Ctr Invest Biomed Red, MP CIBEROBN, Madrid 28029, Spain
Univ Hosp St Joan Reus, Nutr Unit, Reus 43204, Spain
Green Published, gold
|